Pressmeddelanden
Lipigon acquires antisense drug candidates for cardiovascular and metabolic diseases from Secarna
Lipigon acquires antisense drug candidates for cardiovascular and metabolic diseases from Secarna Lipigon Pharmaceuticals ("Lipigon") announced that the company has acquired antisense drug candidates jointly generated with Secarna Pharmaceuticals ("Secarna") under a previous research collaboration. Lipigon will continue the research and development of the acquired assets targeting the ANGPTL gene family, and Secarna will receive undisclosed payments customary for such a transaction.
"We are very pleased with the Secarna collaboration under the target validation agreement. Together we have built a strong patent portfolio and moreover, we have generated a powerful in vivo and in vitro data package. Secarna's impressive LNAplusTM platform has given us fully optimized clinical candidates that we are looking forward to bringing into IND-enabling studies." says CEO and cofounder Stefan K. Nilsson. "The acquisition is in line with Lipigon's business model to fully control our pipeline until out-licensing or market introduction. We believe that this agreement will make our case more attractive for investors".
Inhibiting the ANGPTL gene family members ANGPTL3 and ANGPTL4 will positively affect plasma lipid levels. Drugs targeting these gene products could be used for treating orphan indications such as Familial Chylomicronemia Syndrome or Homozygote Familial Hypercholesterolemia, but also more common diseases such as cardiovascular, metabolic liver and kidney diseases. Antisense therapeutics have recently proven to be very attractive. Several big pharma companies showed major licensing and acquisition agreements in 2019.
"Lipigon has been a great partner throughout our highly productive collaboration. We are excited that Lipigon will advance the LNAplus™ assets and look forward to further data read-outs.", said Jonas Renz, Managing Director and Co-Founder of Secarna.
Umeå March 23rd 2020
For further information, please contact:
Stefan K. Nilsson, CEO, Lipigon Pharmaceuticals
e-mail: stefan@lipigon.se
Tel: +46 70 578 176
About Lipigon Pharmaceuticals
Lipigon are lipid biology experts focusing on developing novel therapeutics for patients with lipidrelated disorders. The company is a spin-off from Umeå University, Sweden, based on five decades of lipid research. Our primary focus is orphan lipid disorders and in addition to the ANGPTL antisense program, Lipigon's pipeline, including a project for gene therapy treatment of lipodystrophy. This program is partnered with Combigene AB (publ). www.lipigon.se.
About Secarna Pharmaceuticals GmbH & Co. KG
Secarna is the next generation antisense oligonucleotide (ASO) company with multiple innovative antisense therapies in various stages of preclinical development in the areas of immuno-oncology, immunology, ophthalmology, as well as viral-, neurodegenerative- and cardiometabolic diseases. www.secarna.com
Lipigon Pharmaceuticals AB ("Lipigon") meddelar i dag att vd Stefan K. Nilsson har köpt aktier i Lipigon till ett sammanlagt värde om 265 tkr till ett genomsnittspris om 3,36 kronor per aktie.
Aktieägarna i Lipigon Pharmaceuticals AB, org.nr 556810-9077, ("Bolaget") kallas härmed till extra bolagsstämma den 19 maj 2022 kl. 11.00 i Bolagets lokaler på Tvistevägen 48C i Umeå.
Styrelsen för Lipigon Pharmaceuticals AB (publ) ("Bolaget" eller "Lipigon") har, villkorat av extra bolagstämmas efterföljande godkännande, beslutat om en nyemission av aktier om cirka 25,1 MSEK med företrädesrätt för Lipigons aktieägare ("Företrädesemissionen"). Företrädesemissionen omfattas till 90 procent av tecknings- och garantiåtaganden. Företrädesemissionen är villkorad av att extra bolagsstämma ("Extra Bolagsstämman") godkänner styrelsens beslut.
Lipigon Pharmaceuticals AB ("Lipigon") offentliggör härmed delårsrapport avseende det första kvartalet 2022. Delårsrapporten i sin helhet finns tillgänglig som bifogad fil samt på bolagets hemsida, www.lipigon.se. Nedan följer en kort sammanfattning av delårsrapporten.
Den 30 april 2022 avslutades nyttjandeperioden för Lipigon Pharmaceuticals AB:s ("Lipigon" eller "Bolaget") teckningsoptioner av serie TO1. Inga teckningsoptioner nyttjades.
Lipigon Pharmaceuticals AB publicerar bolagets årsredovisning för räkenskapsåret 2021.
Lipigon, som i går fick sin ansökan om kliniska prövningar av bolagetsblodfettsänkande läkemedelskandidat Lipisense godkänd av Läkemedelsverket, presenterar på Aktiedagen den 2 maj. Vd Stefan K. Nilsson ger en uppdatering kring Lipisense och vägen framåt för Lipigon.
Lipigon Pharmaceuticals AB, ("Lipigon"), meddelade i dag att bolaget har fått godkänt av Läkemedelsverket på sin ansökan om klinisk prövning av den blodfettssänkande läkemedelskandidaten Lipisense.
Lipigon Pharmaceuticals AB ("Lipigon") today announced that the company has received approval from the Swedish Medical Products Agency to start a clinical phase I study with the lipid-lowering drug candidate Lipisense.
Lipigons vd Stefan K. Nilsson medverkar på Redeyes investerarevent Investor Forum Online tisdag den 26 april.
Aktieägarna i Lipigon Pharmaceuticals AB, org.nr 556810-9077, ("Bolaget") kallas till årsstämma den 19 maj 2022 kl. 10.00 i Bolagets lokaler på Tvistevägen 48C i Umeå.
Nyheter
Lipigons vd Stefan K. Nilsson ökar sitt innehav i bolaget
Lipigon Pharmaceuticals AB ("Lipigon") meddelar i dag att vd Stefan K. Nilsson har köpt aktier i Lip...
Kallelse till extra bolagsstämma i Lipigon Pharmaceuticals AB
Aktieägarna i Lipigon Pharmaceuticals AB, org.nr 556810-9077, ("Bolaget") kallas härmed till extra b...
Lipigon har beslutat om en företrädesemission om 25,1 MSEK
Styrelsen för Lipigon Pharmaceuticals AB (publ) ("Bolaget" eller "Lipigon") har, villkorat av extra ...